EUVIMEDEUVIMED entdecken
Crossref

Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival

Alissa J Cooper iD, Edoardo Garbo iD, Andrea Arfe, Michael Conroy, Narek Shaverdian iD, Matthew Bott, Teresa Gorria, Federica Pecci, Mihaela Aldea, Valsamo Anagnostou, Adam Schoenfeld, Daniel Gomez und 5 weitere

Cancer · 2025

DOI: 10.1002/cncr.70081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Alissa J Cooper und 16 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off‐trial patients who received treatment with neoadjuvant chemoIO.

Methods

The authors analyzed records of patients with stage IB–III NSCLC who received neoadjuvant chemoIO with an intent to proceed to surgical resection at three US academic institutions. Clinical, demographic, and pathologic factors were incorporated in univariable and multivariable regression models to identify associations with outcomes (resection status, pathologic complete response [pCR], and subsequent event‐free survival [EFS]) after standard‐of‐care neoadjuvant chemoIO.

Results

Analyses included 115 patients, of whom 63% had stage III disease, 77% completed three cycles of chemoIO, and 78% underwent surgical resection. Ages older than 72 years versus 64 years and younger were associated with not proceeding to surgery in univariable ( p = .006) and multivariable ( p = .014) regression analyses. Nineteen patients (17%) had tumors with a pCR, and 34 (30%) had a major pathologic response. Positive programmed death‐ligand 1 (PD‐L1) expression (≥50%; vs. negative PD‐L1 expression: odds ratio, 12.1; 95% confidence interval, 2.0–73.7; p = .007) and KRAS mutations (vs. wild‐type KRAS : odds ratio, 3.9; 95% confidence interval, 1.07–14.4; p = .039) were associated with a higher probability of pCR in univariable analysis. The median event‐free survival was not reached and did not differ among subgroups stratified by key clinical variables.

Conclusions

The results from this study confirm the trial experience of high pCR rates after neoadjuvant chemoIO. This supports the use of chemoIO irrespective of KRAS mutation status, PD‐L1 expression, and histology, but suggests that this approach may be less suitable for older patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNeoadjuvant TherapyLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedB7-H1 AntigenTreatment OutcomeRetrospective StudiesImmunotherapyProto-Oncogene Proteins p21(ras)AdultNeoplasm StagingDisease-Free SurvivalPathologic Complete Response

Stichwörter der Autor:innen

locally advancedneoadjuvant chemoimmunotherapynonsmall cell lung cancerpathologic complete responsesurgical resectability

Substanzen

B7-H1 AntigenProto-Oncogene Proteins p21(ras)KRAS protein, humanCD274 protein, human

Autor:innen und Institutionen

  • Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.
  • Lowe Center for Thoracic Oncology, Dana-Farber Cancer Center, Boston, Massachusetts, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Alissa J Cooper, Edoardo Garbo, Narek Shaverdian, Jamie E Chaft

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Cooper, A. J., Garbo, E., Arfe, A., Conroy, M., Shaverdian, N., Bott, M., Gorria, T., Pecci, F., Aldea, M., Anagnostou, V., Schoenfeld, A., Gomez, D., Forde, P. M., Awad, M. M., Jones, D. R., Ricciuti, B., & Chaft, J. E. (2025). Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival. Cancer. https://doi.org/10.1002/cncr.70081

Vancouver

Cooper AJ, Garbo E, Arfe A, Conroy M, Shaverdian N, Bott M, et al. Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival. Cancer. 2025. doi:10.1002/cncr.70081

BibTeX
@article{Cooper2025,
  author = {Cooper, Alissa J and Garbo, Edoardo and Arfe, Andrea and Conroy, Michael and Shaverdian, Narek and Bott, Matthew and Gorria, Teresa and Pecci, Federica and Aldea, Mihaela and Anagnostou, Valsamo and Schoenfeld, Adam and Gomez, Daniel and Forde, Patrick M and Awad, Mark M and Jones, David R and Ricciuti, Biagio and Chaft, Jamie E},
  title = {Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70081}
}
Kostenlos starten →